GlassScriptPhysician profile
April Lee Wilson
NPI 1396458915
$2,746.04
in general payments reported to CMS, 2019-2025
21 companies · $802 in 2025
The $802 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $840 · 2024: $1,104 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,746.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $410.93 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $367.79 | 2023-2025 | |
| Amgen INC. | $346.78 | 2023-2025 | Evenity, Prolia, Otezla |
| Sumitomo Pharma America, INC. | $229.62 | 2023-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $186.73 | 2023-2025 | Cuvitru, Takhzyro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.28 | 2023-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $170.20 | 2023-2024 | |
| Lilly USA, LLC | $153.16 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $130.45 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $118.44 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $106.90 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $88.83 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $50.43 | 2024 | Spravato |
| Daiichi Sankyo INC. | $41.97 | 2024-2025 | Injectafer |
| Axsome Therapeutics, INC. | $34.28 | 2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $29.87 | 2025 | |
| Alexion Pharmaceuticals, INC. | $25.64 | 2023 | Ultomiris |
| Idorsia Pharmaceuticals US INC | $25.50 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $23.14 | 2023 | Recorlev |
| Abbott Laboratories | $19.15 | 2025 | Freestyle Libre 3 |
| Blueprint Medicines Corporation | $12.95 | 2023 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.